X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IOA-289 (cambritaxestat) is a novel, first-in-class inhibitor of autotaxin with a unique binding mode. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Cambritaxestat,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IOA-289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.
Lead Product(s): Roginolisib
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Under the agreement, iOnctura gets exclusive global development rights to IOA-359, a novel oral, small molecule, TGF–β pathway inhibitor that will be evaluated in solid tumors.
Lead Product(s): IOA-359
Therapeutic Area: Oncology Product Name: IOA-359
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clavius Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 03, 2023
Details:
The grant will accelerate iOnctura's preclinical investigation of IOA-359, a novel oral, small molecule, TGF–β pathway inhibitor that will be evaluated in solid tumors.
Lead Product(s): IOA-359
Therapeutic Area: Oncology Product Name: IOA-359
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Health Holland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2023
Details:
IOA-244 (roginolisib) is a first-in-class, non-ATP-competitive, allosteric modulator of PI3K delta which prevents tumor proliferation and breaks immune tolerance in patients with solid and hematological tumors.
Lead Product(s): Roginolisib
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
IOA-244 (roginolisib) is a first-in-class, non-ATP-competitive, allosteric modulator of PI3K which prevents tumor proliferation and breaks immune tolerance in patients with solid and hematological tumors.
Lead Product(s): Roginolisib
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
IOA-244 is a first-in-class semi-allosteric, non-ATP competitive, small molecule PI3Kδ inhibitor which has shown high beneficial tolerability and clinical benefit profile. PI3Kδ over-expression stimulates multiple cancer mechanisms and an oncogenic role in many tumor types.
Lead Product(s): Roginolisib,Avelumab,Pemetrexed
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
IOA-289 is the first ATX inhibitor in clinical development for cancer. It is an oral small molecule non-competitive inhibitor with novel binding chemistry and a safe clinical profile. Inhibiting ATX with IOA-289 directly prevents the proliferation of cancer cells.
Lead Product(s): IOA-289,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IOA-289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Council
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 20, 2022
Details:
IOA-289 is an orally dosed small molecule that has been shown preclinically to have a multi-pronged approach to treating cancer, acting directly to prevent proliferation of tumor cells and indirectly to potentiate the actions of the immune system.
Lead Product(s): IOA-289,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IOA-289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
IOA-244 is a PI3Kδ specific, orally dosed, small molecule inhibitor that overcomes tumor and stroma induced immune suppression. Its unique chemistry, semi allosteric binding mode and mechanism of action contribute to its unprecedented clinical profile.
Lead Product(s): Roginolisib,Avelumab,Pemetrexed
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
